WilmerHale Advises Xilio Therapeutics In $95M Series C Financing

WilmerHale Advises Xilio Therapeutics In $95M Series C Financing

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On February 24, 2021, Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, announced the successful closing of a $95 million Series C financing round. Proceeds from the financing will be used to advance Xilio’s lead therapeutic candidates, XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4 mAb), into clinical trials. The financing was led by Rock Springs Capital and was joined by Bain Capital Life Sciences, Deerfield Management Company and RA Capital Management, among other new investors. Xilio’s existing investors, including Atlas Venture, SV Health Investors, Takeda Ventures, RiverVest Venture Partners, and MRL Ventures Fund, also participated in the financing.

The WilmerHale team representing Xilio Therapeutics was led by Cynthia Mazareas and included Timothy Kulis, Meghan Fay and Elizabeth Brasher.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel